key: cord-0720357-rquo67it authors: Tlayjeh, H.; Mhish, O.; Enani, M.; Alruwaili, A.; Tleyjeh, R.; Thalib, L.; Hassett, L.; Arabi, Y.; Kashour, T.; Tleyjeh, I. title: Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis date: 2020-08-14 journal: nan DOI: 10.1101/2020.08.13.20174201 sha: 72db69c1555710c345733604f84dc52da3265419 doc_id: 720357 cord_uid: rquo67it Background: To systematically review the literature about the effect of systemic corticosteroid therapy (CST) on outcomes of COVID-19 patients. Methods: We searched Medline, Embase, EBM Reviews, Scopus, Web of Science, and preprints up to July 20, 2020. We included observational studies and randomized controlled trials (RCT) that assessed COVID-19 patients treated with CST. We pooled adjusted effect estimates of mortality and other outcomes using a random effect model, among studies at low or moderate risk for bias. We assessed the certainty of evidence for each outcome using the GRADE approach. Results: Out of 1067 citations screened for eligibility, one RCT and 19 cohort studies were included (16,977 hospitalized patients). Ten studies (1 RCT and 9 cohorts) with 10,278 patients examined the effect of CST on short term mortality. The pooled adjusted RR was 0.92 (95% CI 0.69-1.22, I2=81.94 %). This effect was observed across all stages of disease severity. Four cohort studies examined the effect of CST on composite outcome of death, ICU admission and mechanical ventilation need. The pooled adjusted RR was 0.41(0.23-0.73, I2=78.69%). Six cohort studies examined the effect of CST on delayed viral clearance. The pooled adjusted RR was 1.47(95% CI 1.11-1.93, I2=43.38%). Conclusion: Heterogeneous and low certainty cumulative evidence suggests that CST lacks efficacy in reducing short-term mortality while possibly delaying viral clearance in patients hospitalized with COVID-19. Because of the discordant results between the single RCT and observational studies, more research should continue to identify the clinical and biochemical characteristics of patients population that could benefit from CST. The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a major global challenge with the paucity of proven effective therapies. In the majority of SARS-CoV-2 infected individuals, the disease is mild. In a proportion of patients, the immune response becomes dysregulated leading to severe acute lung injury manifesting as adult respiratory distress syndrome (ARDS) and can also lead to multiorgan injury and failure [1, 2] . The hallmark of pulmonary pathology in COVID-19 disease is diffuse alveolar damage, often associated with thickening of alveolar walls with infiltration by inflammatory cells dominated by macrophages and mononuclear cells [3] . It has been also observed that COVID-19 patients develop significant pulmonary vascular endothelial cell injury and endothelialitis, which is associated with intravascular thrombosis and microangiopathy [4, 5] . COVID-19 disease is commonly associated with several elevated inflammatory biomarkers, cytokines and chemokines reaching very high levels in the severe form. Among these are, Creactive protein (CRP), ferritin, tumor necrosis factor-alpha (TNF), interleukins (IL-1, IL-2, IL-6, IL-8, and IL-10), Interferon-gamma, monocyte chemoattractant protein-1 (MCP-1) and granulocyte-macrophage colony stimulating factor (GM-CSF). Moreover, lymphocytopenia and neutrophilia are very common with a significant reduction in the CD8+ T cells, CD4+ T cells, and natural killer (NK) cell populations [1, 2] . The mortality among hospitalized patients ranges between 15% and 20%; however, it exceeds 40% in patients requiring intensive care [3] . Because of high in-hospital mortality, evidence of intense inflammation associated with COVID-19 disease and paucity of specific effective therapy, clinicians were forced to explore potential therapeutic approaches that target inflammation with the rationale to mitigate acute inflammation, reduce tissue injury and improve outcomes. Among the drugs that received early attention were corticosteroids because of their well-known broad-spectrum anti-inflammatory and immunomodulatory effects. Corticosteroids therapy (CST) has been used extensively in acute respiratory conditions, which share similar pathological features with COVID-19 disease like SARS-CoV, MERS-CoV and H1N1 influenza, as well as in community acquired pneumonia (CAP), and ARDS. However, their effectiveness in reducing mortality and improving other outcomes in these conditions remain controversial [6] [7] [8] [9] . Recent attempts to interpret these data led to more controversy regarding the therapeutic potential of CST in severe COVID-19 disease where some authors support and others recommend against their use in this disease [10, 11] . Early experience with CST in severe COVID-19 disease from a small observational study showed promising results in terms of improving survival [12] , but subsequent observational studies and limited data from a single randomized clinical trial revealed mixed results. Since the single large randomized trial (RECOVERY) observed that dexamethasone treatment improves survival in the subgroup of patients with severe and critical COVID-19, CST has been promoted worldwide by physicians and the media as the most important level-I evidence effective COVID-19 therapy. Although a randomized controlled trial (RCT) is considered the gold standard to test the efficacy of any intervention, observational studies help to improve the inference derived from a single RCT, by improving generalizability. Although, the RECOVERY trial was a pragmatic trial with wide eligibility criteria, it used an open label design and it enrolled only 15% of hospitalized patients in the UK during the study period and excluded 17% of eligible patients because of unavailability of dexamethasone or treating physician's decision. Data from observational studies help examine the generalizability of findings. In fact, empirical studies have shown that pooled estimates from meta-analysis of observational studies yield similar estimates to those pooled from RCTs [13, 14] . Moreover, there remain several questions that need to be addressed such as the timing of CST initiation, the dosing and the duration of treatment and disease phenotypes that could affect the efficacy of CST. Finally, observational studies may examine outcomes that are not assessed in RCTs. Therefore, we sought to perform a systematic review of randomized and observational studies addressing the role of CST in the treatment of COVID-19 disease and explore potential sources for heterogeneity of treatment effect in COVID-19 patients. We followed Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines for reporting systematic review [15] . We included 1) RCTs or 2) cohort or case-control studies reporting on the adjusted effect estimates of the association between CST use in COVID-19 patients and one of the following a-priori outcomes: (1) in-hospital mortality, (2) mechanical ventilation, (3) ICU admission, (4) viral shedding and (5) composite outcomes if reported. The search strategy was designed and conducted by an experienced librarian with input from the study's principal investigator. Controlled vocabulary supplemented with keywords was used to search for studies describing CST for the treatment of COVID-19. The actual strategy including search terms used and how they were combined is listed in the supplementary material (Supplement AI: Search Strategy). We also searched for unpublished manuscripts using the medRxiv services operated by Cold Spring Harbor Laboratory and Research Square preprints. In addition, we searched Google Scholar and the references of eligible studies and review articles. Four reviewers independently identified eligible studies (ME, AA, OM, RT) and extracted the data into a pre-specified data collection form. A senior reviewer verified all data included in the analyses (IT). Four reviewers (ME, AA, OM, HT) independently assessed the risk of bias for each study using the (RoB 2) of the Cochrane risk-of-bias tool for randomized trials and the ROBINS-I ("Risk Of Bias In Non-randomized Studies of Interventions") for observational studies [16] . We also assessed all included studies for risk of survivor bias (or immortal time bias). Survivor bias occurs because patients who live longer are more likely to receive treatment than those who die early [17] . We considered the following analytical approaches as acceptable tools to account for survivor bias [8, 17, 18] : (1) CST use as a time-dependent variable in the regression analysis, (2) landmark analysis, (3) structural nested accelerated failure time model, (4) marginal structure models, and (5) matched cohort analysis in which each treated patient is followed up from the treatment start time with a matched control with the same disease duration prior to this time point. Studies that excluded patients who experienced the outcome within 24 hours of admission were considered at moderate risk for survivor bias. Reviewers judged each criterion for risk of bias and resolved any disagreements with a senior reviewer (IT). Finally, we assessed the certainty of evidence for each of our outcomes using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach [19, 20] . This method evaluates the certainty of evidence by assessing the following domains: Limitations, indirectness, inconsistency, imprecision, and publication bias. We evaluated between-studies heterogeneity using the I 2 statistic which estimates the variability percentage in effect estimates that is due to heterogeneity rather than to chance-the larger the I 2 , the greater the heterogeneity [21] . Due to substantial heterogeneity, we pooled the adjusted effect estimates of included studies using the DerSimonian-Laird random-effects model and constructed corresponding forest plots [22] . Prior to pooling, the ORs were converted to RRs using the method by Zhang and Yu [23]. We conducted a priori determined subgroup analyses to assess the impact of (1) COVID-19 disease severity (critical group: patients admitted to intensive care unit (ICU). Severe group: patients requiring respiratory support outside ICU. Non-severe group: patients who did not require any respiratory support), (2) study design (RCT vs. cohort studies), (3) CST doses (low dose: methylprednisolone <= 1mg/kg/d or equivalence. High dose: methylprednisolone >1mg/kg/d or equivalence), (4) adjustment for survivor bias, on the overall estimate of effect. We also conducted meta-regression using study level baseline characteristics of patients' populations and constructed corresponding bubble plots [24] . Due to missing data, we were able to examine only a few variables. Finally, we constructed contour-enhanced funnel plots and performed an Egger precision-weighted linear regression test as a statistical test of funnel plot asymmetry and publication bias [25] . All analyses were conducted using Stata version 16 statistical software (StataCorp, College Station, Texas). A total of 24 studies (1 RCT, 23 cohorts) [26-49] with 16977 patients, including single center and multicenter studies from different countries, were included in our systematic review. Figure 1 shows the result of our search strategy (PRISMA flow diagram). Table 1 illustrates the general characteristics of the included studies. All studies reported on patients hospitalized with COVID-19 with varying degrees of disease severity. The quality of the observational studies was assessed using ROBINS-I tool ( Figure 2B ). Four studies were excluded from analysis because of serious risk of bias [27, 29, 36, 38] . Among included studies, immortal time bias was addressed in the analysis in only 3 ( Table 2 ). The pooled RRs and corresponding ARRs and GRADE certainty of evidence are summarized in Table 2 . Ten studies (1 RCT, 9 cohorts) [26, 31, 33, 35, 37, 39, 42, 46, 49] examined the effect of CST on short-term mortality in hospitalized patients with COVID-19. The pooled adjusted RR was 0.91 (95% CI 0.71-1.16, I 2 = 82.23 %) indicating no significant association between CST and mortality ( Figure 2A ). There was significant heterogeneity between the studies. Contoured enhanced funnel plot showed no evidence of publication bias (Supplement AII: Figure1). On univariate meta-regression analysis, DM and male sex were associated with RR of mortality. The higher the prevalence of DM or male sex in included studies, the lower the reported RR for mortality (Supplement AII: Figure 2 was no significant association between CST and short-term mortality across all the disease severity groups ( Figure 3A ). There was also no association between CST and mortality regardless of CST dose (pooled adjusted RR 0.95 (95% CI 0.74-1.22, I 2 =78.59%) for low dose and RR 0.97 (95%CI 0.07-13.31, I 2 =92.98%) for high dose (Supplement AII: Figure 3 ). Restricting the analysis to studies that adjusted for survivor bias showed no association between CST and mortality; pooled adjusted RR 1.03 (95% CI 0.75-1.42, I 2 =82.49%) [26, 46] (Supplement AII: Figure 4 ). Four cohort studies [30, 32, 37, 42] examined the effect of CST on composite outcome of death, ICU admission and mechanical ventilation need in patients with severe COVID-19. The pooled adjusted RR was 0.41(95% CI 0.23-0.73, I 2 =78.69%) (Supplement AII: Figure 5 ). Three studies (1 RCT, 2 cohorts) [26, 37, 40] showed no association between treatment with CST and mechanical ventilation need. The pooled adjusted RR was 0.74 (95% CI 0.50-1.09, I 2 =74.15%) (Supplement AII: Figure 6 ). Six cohort studies examined the effect of CST on viral clearance [28, 41, 43, 45, 47, 48] . Viral clearance is defined as two consecutive negative RT-PCR swabs separated by at least 24 hours. Delayed viral clearance was not uniformly defined but most studies defined it as persistent positive RT-PCR swabs for more than 11 to 17 days from first positive test. The six included patients with COVID-19 with variable degree of disease severity. CST was associated with delayed viral clearance; pooled adjusted RR was 1.47 (95% CI 1.11-1.93, I 2 =43.38%) ( Figure 3B ). The RECOVERY trial did not assess the effect of CST on viral clearance. This systematic review and meta-analysis included 19 cohorts and 1 RCT, with low to moderate risk of bias, which addressed the association between CST and mortality, disease progression, and viral clearance in patients hospitalized with COVID-19 disease. Although the single pragmatic RECOVERY randomized trial showed that CST was associated with lower mortality in severe and critical COVID-19, we could not observe the same effect in our large meta-analysis of 16977 patients. We found with very low level of certainty, that CST did not reduce short-term mortality among COVID-19 patients. However, in a smaller number of studies (4 cohorts) that reported on composite outcomes, we found with very low level of certainty (due to heterogeneity) an association between CST and a decreased risk of the composite outcome (death, ICU admission, and mechanical ventilation need). These observations did not change when we restricted our analysis to studies that adjusted for survivor bias. We also found similar results across all stages of disease severity, critical, severe, and non-severe. All meta-analyses were limited by significant between-studies heterogeneity that could not be explained by disease severity, high vs. low dose of corticosteroids. On the other hand, we found that CST could prolong viral shedding, and in a single study that examined the risk of secondary infections, CST was associated with an increased risk of acquired bloodstream infections [34] . Although the cumulative evidence from our meta-analysis is discordant with the single RCT (RECOVERY), it should not be disregarded as inferior evidence in the presence of this RCT. First, the RECOVERY trial had an open label design which could make it susceptible to performance (co-intervention) bias that usually inflicts observational studies. Second, it was conducted in a single country and the baseline mortality for patients with mild and severe disease was higher relative to that reported from other countries which makes the results less generalizable to different patients' populations. Third, although the RECOVERY trial due to its pragmatic design was an exceptional achievement during the pandemic, only 15% of hospitalized patients in UK were enrolled and 17% of eligible patients were excluded from enrollment in this RCT because dexamethasone was either not available, or it was believed to be indicated or contraindicated by the treating physicians. Fourth, despite compelling evidence from RCTs, observational studies if appropriately designed and analyzed provide important evidence from real-life data. Observational studies and meta-analyses of these studies may offer higher external validity than a single RCT owing to their potentially large size and the ability to include a patient sample that is representative of the average patient population. Fourth, there are additional important differences between RCTs and observational studies, such as standardized patients care with protocols and exclusion of certain patients' groups in RCTs [50] . Our findings of lack of efficacy of CST in reducing mortality among COVID-19 patients is concordant with previous observations in other coronavirus infections associated acute lung injury, namely SARS-CoV and MERS-CoV. In a systematic review of 29 studies of CST in SARS-CoV infection, the results of 25 studies were inconclusive while four studies showed possible harm [7] . Similarly, in a recent systematic review that included two large cohorts with 6129 SARS-CoV patients, CST did not show a significant reduction in mortality (HR 0.83, 95% CI 0.41-1.66) [9] . Lack of efficacy of CST in reducing mortality was also shown in MERS-CoV infection. In a multicenter study of 309, the crude mortality was higher in the corticosteroid treated group (74.2% vs. 57.6%, p=0.002) but the adjusted mortality was not different (adjusted OR 0.78, 95% CI 0.52-1.07, p=0.12) [8] . On the other hand, CST was associated with increased mortality among influenza A H1N1 patients. In a systematic review and meta-analysis of 10 observational studies involving 6548 patients, CST was associated with increased (risk ratio The patients in our meta-analysis were very heterogeneous and that could explain the lack of efficacy of CST in improving outcomes in general but could be helpful in certain phenotypes as shown in the subgroup analysis of the RECOVERY trial. We could not explore all possible causes of between-studies heterogeneity with the metaregression analysis such inflammatory markers levels (CRP, D-Dimer, IL-6) because of inadequate data reporting in included studies. The dose of corticosteroids used in the RECOVERY trial was dexamethasone 6 mg per day (methylprednisolone equivalence 32 mg, <0.5mg/kg/d for an average 70 kg person). All the cohort studies included in our systematic review used higher doses of steroids. High dose corticosteroids are associated with more serious adverse effects like serious hyperglycemia, gastrointestinal bleeding, neuropsychiatric events, and superinfection [9] . However, looking at subgroups of studies that used <=1 mg/kg/d vs >1 mg/kg/d of methylprednisolone equivalence showed no effect on mortality regardless of the dose used. Consistent with our observation, In a priori subgroup analysis of the RECOVERY trial, the patients who benefited most from CST are patients who were commenced on CST more than 7 days from onset of symptoms which may correlate with the start of dysregulated immune system. We could not assess the effect of CST timing in our systematic review because of inadequate data. The timing of CST in the disease stage likely play a vital role in modulating the immune response and outcome. Lucas et al found that nasopharyngeal viral load correlates positively with plasma levels of interferon and cytokines. Patients with severe disease did not show any decline in viral load over the course of their disease [53]. We observed a significant association between CST and prolonged viral RNA shedding, pooled RR 1.47 (1.11-1.93) which is consistent with previous data in other viral infections such as SARS-CoV, MERS-CoV and influenza [7, 8, 62] . Prolonged viral RNA shedding is often used as a surrogate for viral replication but the correlation between prolonged viral RNA shedding and infectivity and other clinical outcomes is unknown. Our meta-analysis has several strengths. Firstly, published, and unpublished studies were included, which reduces publication bias. We also employed rigorous methodologies. We excluded studies that were prone to significant confounding because they did not report adjusted odds or hazard ratios. We also examined mortality and other clinical outcomes separately and performed sensitivity analyses to explore sources of between studies heterogeneity. However, our study has several limitations; all our included studies except one were observational studies which are prone to different biases; including confounding by indication, survivor (immortal time) bias and residual confounding. Our group and others have shown that survivor bias, which occurs because patients who live longer are more likely to receive treatment than those who die early, could change associations from benefit to harm [8, 17, 63] . Only one observational study has adjusted for survivor bias [46] and in this single study, CST was associated with a higher mortality in both severe and critical subgroups. Moreover, as with all observational studies, residual confounding could inflict any observed association [64] even with appropriate adjustment or propensity score matching. Nevertheless, the direction of these different biases is supposed to be in favor of corticosteroids efficacy, which was not observed in our analysis. We found in this systematic review and meta-analysis that heterogeneous and low certainty cumulative evidence suggests that CST lacks efficacy in reducing short-term mortality while possibly delaying viral clearance in patients hospitalized with COVID-19. Because of the discordant results between the single RCT and observational studies, more research should continue to identify the clinical and biochemical characteristics of patients' population that could benefit from CST and the optimal dose and duration of treatment. Li C r o t t y e t a l , 2 0 2 0 U S A 2 8 9 M u l t i c e n t e r o b s e r v a t i o n a l c o h o r t M u l t i v a r i a b l e C o x r e g r e s s i o n H o s p i t a l i z e d p a t i e n t s w i t h C O V I D -1 9 c o r t i c o s t e r o i d s R e s p i r a t o r y b a c t e r i a l c o i n f e c t i o n s I n -h o s p i t a l m o r t a l i t y , I C U a d m i s s i o n , m e c h a n i c a l v e n t i l a t i o n , L O S A g e , I C U a d m i s s i o n , M V , s t e r o i e r i o u s i n c o n s i s t e n c y ) i n c r e a s e t h e r i s k o f a c q u i r e d b l o o d s t r e a m i n f e c t i o n s i n p a t i e n t s w i t h C O V I D -1 9 Clinical and immunological features of severe and moderate coronavirus disease 2019 The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): A review Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19 Endothelial cell infection and endotheliitis in COVID-19 Pharmacological agents for adults with acute respiratory distress syndrome SARS: systematic review of treatment effects Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis On the use of corticosteroids for 2019-nCoV pneumonia Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials Should meta-analyses of interventions include observational studies in addition to